I hope it will be developed. But development of HBY 097 was in fact terminated. The compound's short half-life in the body and large required dose led to an onerous dosing schedule and concerns about possible toxicities and interactions with other drugs. Reproduced with permission. Inc. All rights reserved.
Noncommercial reproduction is encouraged.
Subscription lists are kept confidential. Always watch for outdated information. This article first appeared in 1998. This material is designed to support, not replace, the relationship that exists between you and your doctor. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only.